Pain Outcomes After Digital Amputation Using Tulavi Allay™ Nerve Cap
Recruiting
Phase 2
Interventional Study
Neuroma
Neuropathic Pain
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 22 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 20 (estimated)
- Sponsor
- Massachusetts General Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
In 2016, one in five individuals in the United States (US) experienced chronic pain, and approximately 40% of them suffered from neuropathic pain. The physical and emotional burden on patients results in costs of billions of dollars annually. Digital amputations affect over 23,000 people each year in the US and may lead to neuropathic pain and neuroma formation in the transected nerves. Previous s…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients undergoing traumatic amputation of a single or multiple digits at MGB
* English-speaking
Exclusion Criteria:
* Patients undergoing revision amputation or non-traumatic amputation
* Patients under 22 years old
* Patients who are pregnant and/or breastfeeding
* Unable…
Contacts